+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Therapeutic Vaccines - Global Strategic Business Report

  • PDF Icon

    Report

  • 182 Pages
  • November 2024
  • Region: Global
  • Global Industry Analysts, Inc
  • ID: 5309838
The global market for Therapeutic Vaccines was estimated at US$39.9 Billion in 2023 and is projected to reach US$117.1 Billion by 2030, growing at a CAGR of 16.6% from 2023 to 2030. This comprehensive report provides an in-depth analysis of market trends, drivers, and forecasts, helping you make informed business decisions.

Why Are Therapeutic Vaccines Garnering So Much Attention?

Therapeutic vaccines, designed to treat existing diseases by stimulating the immune system to fight off illness, have become a cornerstone in modern medicine. Unlike traditional vaccines that focus on preventing infections, therapeutic vaccines target ongoing diseases such as cancer, chronic infections, and autoimmune disorders. The increasing prevalence of cancer and the growing interest in immunotherapy as a viable treatment option are key drivers in this market. Therapeutic vaccines hold the promise of revolutionizing treatment for patients who have not responded to conventional therapies, making this a highly dynamic and rapidly growing segment within the broader vaccine market.

How Are the Various Segments of the Therapeutic Vaccines Market Expanding?

Notable segments include vaccines targeting infectious diseases like HIV and hepatitis, as well as autoimmune disorders. Technology plays a crucial role in the development of these vaccines, with advances in mRNA, dendritic cell-based vaccines, and viral vectors driving significant progress. The end-user segments primarily include hospitals, cancer treatment centers, and research institutions, which are playing an instrumental role in conducting clinical trials and early-phase research on novel therapeutic vaccines.

What Technological and Regulatory Trends Are Shaping the Market?

The therapeutic vaccine market has been greatly influenced by innovations in biotechnology, particularly with the rise of personalized medicine and next-generation sequencing. Advances in understanding the immune system and tumor biology have led to the development of vaccines that are highly specific to individual patients, driving the market's growth. Additionally, regulatory approvals for cancer vaccines, such as those targeting HPV and prostate cancer, have opened the door for further innovation in the field. Another key trend is the increasing collaboration between pharmaceutical companies and academic research institutes to accelerate vaccine development. Government initiatives and funding to support vaccine research are also providing a strong foundation for market growth.

What Are the Key Factors Driving Growth in the Therapeutic Vaccines Market?

The growth in the therapeutic vaccines market is driven by several factors, including the rising incidence of cancer and chronic infectious diseases, advancements in vaccine development technologies, and the growing number of clinical trials for therapeutic vaccines. Increased investments from pharmaceutical companies in R&D and the expansion of vaccine manufacturing infrastructure are critical drivers of market growth. Additionally, rising public awareness of immunotherapy and its potential benefits is fueling demand for therapeutic vaccines. Regulatory support in the form of fast-tracking approvals and orphan drug status for certain therapeutic vaccines is also contributing to market expansion. Finally, the global push for more effective cancer treatments is propelling significant growth in this market, especially as personalized vaccines gain traction.

Key Insights:

  • Market Growth: Understand the significant growth trajectory of the Autoimmune Disease Vaccines segment, which is expected to reach US$62.8 Billion by 2030 with a CAGR of a 17.2%. The Neurological Disease Vaccines segment is also set to grow at 17.5% CAGR over the analysis period.
  • Regional Analysis: Gain insights into the U.S. market, which was valued at $10.6 Billion in 2023, and China, forecasted to grow at an impressive 21.9% CAGR to reach $29.2 Billion by 2030. Discover growth trends in other key regions, including Japan, Canada, Germany, and the Asia-Pacific.

Why You Should Buy This Report:

  • Detailed Market Analysis: Access a thorough analysis of the Global Therapeutic Vaccines Market, covering all major geographic regions and market segments.
  • Competitive Insights: Get an overview of the competitive landscape, including the market presence of major players across different geographies.
  • Future Trends and Drivers: Understand the key trends and drivers shaping the future of the Global Therapeutic Vaccines Market.
  • Actionable Insights: Benefit from actionable insights that can help you identify new revenue opportunities and make strategic business decisions.

Key Questions Answered:

  • How is the Global Therapeutic Vaccines Market expected to evolve by 2030?
  • What are the main drivers and restraints affecting the market?
  • Which market segments will grow the most over the forecast period?
  • How will market shares for different regions and segments change by 2030?
  • Who are the leading players in the market, and what are their prospects?

Report Features:

  • Comprehensive Market Data: Independent analysis of annual sales and market forecasts in US$ Million from 2023 to 2030.
  • In-Depth Regional Analysis: Detailed insights into key markets, including the U.S., China, Japan, Canada, Europe, Asia-Pacific, Latin America, Middle East, and Africa.
  • Company Profiles: Coverage of major players such as Agenus, Inc., Bavarian Nordic A/S, CEL-SCI Corporation, and more.
  • Complimentary Updates: Receive free report updates for one year to keep you informed of the latest market developments.

Select Competitors (Total 13 Featured):

  • Agenus, Inc.
  • Bavarian Nordic A/S
  • CEL-SCI Corporation
  • Dendreon Corporation
  • GlaxoSmithKline PLC
  • Novartis International AG
  • Oncothyreon, Inc.
  • TVAX Biomedical Inc.
  • Vical, Inc.

Table of Contents

I. METHODOLOGYII. EXECUTIVE SUMMARY
1. MARKET OVERVIEW
  • Influencer Market Insights
  • World Market Trajectories
  • Impact of COVID-19 and a Looming Global Recession
  • Therapeutic Vaccines - Global Key Competitors Percentage Market Share in 2024 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
2. FOCUS ON SELECT PLAYERS
3. MARKET TRENDS & DRIVERS
  • Rising Focus on Cancer Immunotherapy Drives Demand for Therapeutic Vaccines
  • Increasing Number of Clinical Trials for Therapeutic Vaccines Expands Market Potential
  • Advances in mRNA Vaccine Technology Propel Growth in Therapeutic Vaccines
  • Growing Prevalence of Chronic Infectious Diseases Generates Demand for Therapeutic Vaccines
  • Increased Public Awareness of Preventative and Therapeutic Vaccines Spurs Demand
  • Development of Personalized Therapeutic Vaccines Expands Market Opportunities
  • Growing Use of Therapeutic Vaccines in Oncology Propels Market Expansion
  • Technological Advancements in Vaccine Delivery Systems Fuel Innovation in Therapeutic Vaccines
  • Rising Focus on Preventive Healthcare Strengthens the Business Case for Therapeutic Vaccines
  • Expansion of Vaccine Manufacturing Infrastructure Drives Market Demand
  • Increased Adoption of Therapeutic Vaccines in Developing Markets Expands Addressable Market
  • Global Vaccination Campaigns Against Emerging Diseases Propel Therapeutic Vaccine Market
4. GLOBAL MARKET PERSPECTIVE
  • Table 1: World Therapeutic Vaccines Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
  • Table 2: World Recent Past, Current & Future Analysis for Therapeutic Vaccines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • Table 3: World Historic Review for Therapeutic Vaccines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 4: World 16-Year Perspective for Therapeutic Vaccines by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2024 & 2030
  • Table 5: World Recent Past, Current & Future Analysis for Autoimmune Disease Vaccines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • Table 6: World Historic Review for Autoimmune Disease Vaccines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 7: World 16-Year Perspective for Autoimmune Disease Vaccines by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
  • Table 8: World Recent Past, Current & Future Analysis for Neurological Disease Vaccines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • Table 9: World Historic Review for Neurological Disease Vaccines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 10: World 16-Year Perspective for Neurological Disease Vaccines by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
  • Table 11: World Recent Past, Current & Future Analysis for Infectious Disease Vaccines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • Table 12: World Historic Review for Infectious Disease Vaccines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 13: World 16-Year Perspective for Infectious Disease Vaccines by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
  • Table 14: World Recent Past, Current & Future Analysis for Addiction Vaccines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • Table 15: World Historic Review for Addiction Vaccines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 16: World 16-Year Perspective for Addiction Vaccines by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
III. MARKET ANALYSIS
UNITED STATES
  • Therapeutic Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
  • Table 17: USA Recent Past, Current & Future Analysis for Therapeutic Vaccines by Product - Autoimmune Disease Vaccines, Neurological Disease Vaccines, Infectious Disease Vaccines and Addiction Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 18: USA Historic Review for Therapeutic Vaccines by Product - Autoimmune Disease Vaccines, Neurological Disease Vaccines, Infectious Disease Vaccines and Addiction Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 19: USA 16-Year Perspective for Therapeutic Vaccines by Product - Percentage Breakdown of Value Sales for Autoimmune Disease Vaccines, Neurological Disease Vaccines, Infectious Disease Vaccines and Addiction Vaccines for the Years 2014, 2024 & 2030
CANADA
  • Table 20: Canada Recent Past, Current & Future Analysis for Therapeutic Vaccines by Product - Autoimmune Disease Vaccines, Neurological Disease Vaccines, Infectious Disease Vaccines and Addiction Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 21: Canada Historic Review for Therapeutic Vaccines by Product - Autoimmune Disease Vaccines, Neurological Disease Vaccines, Infectious Disease Vaccines and Addiction Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 22: Canada 16-Year Perspective for Therapeutic Vaccines by Product - Percentage Breakdown of Value Sales for Autoimmune Disease Vaccines, Neurological Disease Vaccines, Infectious Disease Vaccines and Addiction Vaccines for the Years 2014, 2024 & 2030
JAPAN
  • Therapeutic Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
  • Table 23: Japan Recent Past, Current & Future Analysis for Therapeutic Vaccines by Product - Autoimmune Disease Vaccines, Neurological Disease Vaccines, Infectious Disease Vaccines and Addiction Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 24: Japan Historic Review for Therapeutic Vaccines by Product - Autoimmune Disease Vaccines, Neurological Disease Vaccines, Infectious Disease Vaccines and Addiction Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 25: Japan 16-Year Perspective for Therapeutic Vaccines by Product - Percentage Breakdown of Value Sales for Autoimmune Disease Vaccines, Neurological Disease Vaccines, Infectious Disease Vaccines and Addiction Vaccines for the Years 2014, 2024 & 2030
CHINA
  • Therapeutic Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
  • Table 26: China Recent Past, Current & Future Analysis for Therapeutic Vaccines by Product - Autoimmune Disease Vaccines, Neurological Disease Vaccines, Infectious Disease Vaccines and Addiction Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 27: China Historic Review for Therapeutic Vaccines by Product - Autoimmune Disease Vaccines, Neurological Disease Vaccines, Infectious Disease Vaccines and Addiction Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 28: China 16-Year Perspective for Therapeutic Vaccines by Product - Percentage Breakdown of Value Sales for Autoimmune Disease Vaccines, Neurological Disease Vaccines, Infectious Disease Vaccines and Addiction Vaccines for the Years 2014, 2024 & 2030
EUROPE
  • Therapeutic Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
  • Table 29: Europe Recent Past, Current & Future Analysis for Therapeutic Vaccines by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • Table 30: Europe Historic Review for Therapeutic Vaccines by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 31: Europe 16-Year Perspective for Therapeutic Vaccines by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2024 & 2030
  • Table 32: Europe Recent Past, Current & Future Analysis for Therapeutic Vaccines by Product - Autoimmune Disease Vaccines, Neurological Disease Vaccines, Infectious Disease Vaccines and Addiction Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 33: Europe Historic Review for Therapeutic Vaccines by Product - Autoimmune Disease Vaccines, Neurological Disease Vaccines, Infectious Disease Vaccines and Addiction Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 34: Europe 16-Year Perspective for Therapeutic Vaccines by Product - Percentage Breakdown of Value Sales for Autoimmune Disease Vaccines, Neurological Disease Vaccines, Infectious Disease Vaccines and Addiction Vaccines for the Years 2014, 2024 & 2030
FRANCE
  • Therapeutic Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
  • Table 35: France Recent Past, Current & Future Analysis for Therapeutic Vaccines by Product - Autoimmune Disease Vaccines, Neurological Disease Vaccines, Infectious Disease Vaccines and Addiction Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 36: France Historic Review for Therapeutic Vaccines by Product - Autoimmune Disease Vaccines, Neurological Disease Vaccines, Infectious Disease Vaccines and Addiction Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 37: France 16-Year Perspective for Therapeutic Vaccines by Product - Percentage Breakdown of Value Sales for Autoimmune Disease Vaccines, Neurological Disease Vaccines, Infectious Disease Vaccines and Addiction Vaccines for the Years 2014, 2024 & 2030
GERMANY
  • Therapeutic Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
  • Table 38: Germany Recent Past, Current & Future Analysis for Therapeutic Vaccines by Product - Autoimmune Disease Vaccines, Neurological Disease Vaccines, Infectious Disease Vaccines and Addiction Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 39: Germany Historic Review for Therapeutic Vaccines by Product - Autoimmune Disease Vaccines, Neurological Disease Vaccines, Infectious Disease Vaccines and Addiction Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 40: Germany 16-Year Perspective for Therapeutic Vaccines by Product - Percentage Breakdown of Value Sales for Autoimmune Disease Vaccines, Neurological Disease Vaccines, Infectious Disease Vaccines and Addiction Vaccines for the Years 2014, 2024 & 2030
ITALY
  • Table 41: Italy Recent Past, Current & Future Analysis for Therapeutic Vaccines by Product - Autoimmune Disease Vaccines, Neurological Disease Vaccines, Infectious Disease Vaccines and Addiction Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 42: Italy Historic Review for Therapeutic Vaccines by Product - Autoimmune Disease Vaccines, Neurological Disease Vaccines, Infectious Disease Vaccines and Addiction Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 43: Italy 16-Year Perspective for Therapeutic Vaccines by Product - Percentage Breakdown of Value Sales for Autoimmune Disease Vaccines, Neurological Disease Vaccines, Infectious Disease Vaccines and Addiction Vaccines for the Years 2014, 2024 & 2030
UNITED KINGDOM
  • Therapeutic Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
  • Table 44: UK Recent Past, Current & Future Analysis for Therapeutic Vaccines by Product - Autoimmune Disease Vaccines, Neurological Disease Vaccines, Infectious Disease Vaccines and Addiction Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 45: UK Historic Review for Therapeutic Vaccines by Product - Autoimmune Disease Vaccines, Neurological Disease Vaccines, Infectious Disease Vaccines and Addiction Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 46: UK 16-Year Perspective for Therapeutic Vaccines by Product - Percentage Breakdown of Value Sales for Autoimmune Disease Vaccines, Neurological Disease Vaccines, Infectious Disease Vaccines and Addiction Vaccines for the Years 2014, 2024 & 2030
SPAIN
  • Table 47: Spain Recent Past, Current & Future Analysis for Therapeutic Vaccines by Product - Autoimmune Disease Vaccines, Neurological Disease Vaccines, Infectious Disease Vaccines and Addiction Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 48: Spain Historic Review for Therapeutic Vaccines by Product - Autoimmune Disease Vaccines, Neurological Disease Vaccines, Infectious Disease Vaccines and Addiction Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 49: Spain 16-Year Perspective for Therapeutic Vaccines by Product - Percentage Breakdown of Value Sales for Autoimmune Disease Vaccines, Neurological Disease Vaccines, Infectious Disease Vaccines and Addiction Vaccines for the Years 2014, 2024 & 2030
RUSSIA
  • Table 50: Russia Recent Past, Current & Future Analysis for Therapeutic Vaccines by Product - Autoimmune Disease Vaccines, Neurological Disease Vaccines, Infectious Disease Vaccines and Addiction Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 51: Russia Historic Review for Therapeutic Vaccines by Product - Autoimmune Disease Vaccines, Neurological Disease Vaccines, Infectious Disease Vaccines and Addiction Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 52: Russia 16-Year Perspective for Therapeutic Vaccines by Product - Percentage Breakdown of Value Sales for Autoimmune Disease Vaccines, Neurological Disease Vaccines, Infectious Disease Vaccines and Addiction Vaccines for the Years 2014, 2024 & 2030
REST OF EUROPE
  • Table 53: Rest of Europe Recent Past, Current & Future Analysis for Therapeutic Vaccines by Product - Autoimmune Disease Vaccines, Neurological Disease Vaccines, Infectious Disease Vaccines and Addiction Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 54: Rest of Europe Historic Review for Therapeutic Vaccines by Product - Autoimmune Disease Vaccines, Neurological Disease Vaccines, Infectious Disease Vaccines and Addiction Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 55: Rest of Europe 16-Year Perspective for Therapeutic Vaccines by Product - Percentage Breakdown of Value Sales for Autoimmune Disease Vaccines, Neurological Disease Vaccines, Infectious Disease Vaccines and Addiction Vaccines for the Years 2014, 2024 & 2030
ASIA-PACIFIC
  • Therapeutic Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
  • Table 56: Asia-Pacific Recent Past, Current & Future Analysis for Therapeutic Vaccines by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • Table 57: Asia-Pacific Historic Review for Therapeutic Vaccines by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 58: Asia-Pacific 16-Year Perspective for Therapeutic Vaccines by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2024 & 2030
  • Table 59: Asia-Pacific Recent Past, Current & Future Analysis for Therapeutic Vaccines by Product - Autoimmune Disease Vaccines, Neurological Disease Vaccines, Infectious Disease Vaccines and Addiction Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 60: Asia-Pacific Historic Review for Therapeutic Vaccines by Product - Autoimmune Disease Vaccines, Neurological Disease Vaccines, Infectious Disease Vaccines and Addiction Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 61: Asia-Pacific 16-Year Perspective for Therapeutic Vaccines by Product - Percentage Breakdown of Value Sales for Autoimmune Disease Vaccines, Neurological Disease Vaccines, Infectious Disease Vaccines and Addiction Vaccines for the Years 2014, 2024 & 2030
AUSTRALIA
  • Therapeutic Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2024 (E)
INDIA
  • Therapeutic Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2024 (E)
SOUTH KOREAREST OF ASIA-PACIFIC
LATIN AMERICA
  • Therapeutic Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2024 (E)
ARGENTINABRAZILMEXICOREST OF LATIN AMERICA
MIDDLE EAST
  • Therapeutic Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2024 (E)
IRANISRAELSAUDI ARABIAUNITED ARAB EMIRATESREST OF MIDDLE EAST
AFRICA
  • Therapeutic Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2024 (E)
IV. COMPETITION

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • Agenus, Inc.
  • Bavarian Nordic A/S
  • CEL-SCI Corporation
  • Dendreon Corporation
  • GlaxoSmithKline PLC
  • Novartis International AG
  • Oncothyreon, Inc.
  • TVAX Biomedical Inc.
  • Vical, Inc.

Table Information